InvestorsHub Logo

TexasMarvL

03/05/22 1:21 PM

#3159 RE: Devolution #3158

I agree the annual fee is peanuts.

I guess I still worry that even with the 510K FDA approved status, there are still some regulatory hurdles that have to be cleared.

However, AXIM has Barry Craig under contract to clear those hurdles.

Barry's accomplishments as described by the release are extensive. He sounds like the best person for the job to clear the final hurdles and put AXIM on the right path of rolling these projects out the right way. AXIM needed a guy like Barry.

Actually, the fact that AXIM hired Barry gives me confidence.
Barry's background with setting up CLIA approved labs gives me confidence. AXIM putting together the medical advisory board for the eye segment gives me confidence.

Listen, I will be happy to celebrate the success of the DED segment and the success of AXIM and give John Huemoeller the credit he deserves for taking a company from no products to a company that becomes profitable with DED that can fund their extensive cancer diagnostic business.

kayakzz

03/05/22 4:48 PM

#3160 RE: Devolution #3158

I have been researching this company and I am seeing a huge number of serious red flags.